ReviewJournal for immunotherapy of cancer2025

High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?

Paul M Sondel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.